This Engineer is Building a ‘Better’ Biopsy

By Cody R. Barnett, MRA Director of Communications | 20 March 2019 In Science

Biopsies are an important tool to determine if a mole or other lesion is cancerous. For most patients, the occasional biopsy is no big deal. However for patients facing multiple abnormal or otherwise ‘suspicious’ spots in highly visible places the prospect can be daunting. Dr. Jesse Wilson, an MRA-funded investigator, is an engineer on a mission to build a better biopsy.

Read More


Bronze Bodies and Black Lungs: Five Ways the Tanning and Tobacco Industries Use the Same Playbook

By Charles Brodine, MRA Intern | 17 March 2019 In Prevention, Science

Dr. Alan Blum has crusaded against the tobacco industry for 30 years and now he's taking aim at the tanning industry. According to Blum, both the tobacco and tanning industries exploit people in similar ways, by targeting youth, downplaying their own corporate responsibility, infiltrating pop-culture, and indeed, by becoming prolific icons.

Read More


Is it Working? Imaging the Immune Response in Melanoma

14 March 2019

Traditional imaging – such as MRIs or CAT scans – provide insight into the effectiveness of immunotherapy by measuring tumor size. While this works, some patients may take months to respond to immunotherapy and in other cases, tumors may appear to actually grow on these scans, falsely indicating progression.

Read More


How Jaqueline’s Promise and Persistence Paid Off

5 March 2019 In Melanoma Stories

Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.

Read More


Fight Back Give Back with Clinical Trials

By Cody R. Barnett, MRA Director of Communications | 24 February 2019 In News, Science

When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


It’s Not that Simple: Young Women and Melanoma

By Cody R. Barnett, MRA Director of Communications | 15 February 2019 In Prevention, Science

Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.

Read More


Doing Good in Rebecca's Name

7 February 2019 In Melanoma Stories

It was March of 2005 when Christine Garrison’s life changed forever. She received the phone call that no mother ever wants to receive. Her daughter Rebecca’s suspicious mole was, in fact, Stage 3 melanoma.

Read More


UV4Me Reaches Young Adults About Sun Safety

By Cody R. Barnett, MRA Director of Communications | 1 February 2019 In Allies & Partnerships, Prevention

Among young people, rates of melanoma are especially alarming. It is now the second most-common cancer among young women aged 20 – 29. While many programs focus specifically on children, studies suggest that we receive over half of our lifetime exposure to UV after the age of 20. Yet, few evidence-based programs focus specifically on the needs of young adults.

Read More


Unchartered Territory: When Should Patients Stop Immunotherapy?

By Cody R. Barnett, MRA Director of Communications | 23 January 2019 In Melanoma Stories, Science, Treatment

For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?

Read More


Login

×